Michael Raymond Appel

US Patent:

7501124, Mar 10, 2009

Filed:

Oct 7, 2004

Appl. No.:

10/962033

Inventors:

Randolph J. Noelle - Cornish NH, US
Fiona H. Durie - Lebanon NH, US
David C. Parker - Portland OR, US
Michael C. Appel - Golden CO, US
Nancy E. Phillips - Shrewsbury MA, US
John P. Mordes - Newton MA, US
Dale L. Grenier - Hubbardston MA, US
Aldo A. Rossini - Sudbury MA, US

Assignee:

Trustees of Dartmouth College - Hanover NH
University of Massachusetts - Boston MA

International Classification:

A61K 39/395
A61K 35/26
A61K 35/28
C07K 16/28

US Classification:

4241541, 424 937, 424 9371, 4241301, 4241331, 4241411, 4241431, 4241441, 4241531, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873, 53038875

Abstract:

Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.

US Patent:

59025859, May 11, 1999

Filed:

Aug 5, 1997

Appl. No.:

8/906332

Inventors:

Randolph J. Noelle - Cornish NH
Fiona H. Durie - Seattle WA
David C. Parker - Grafton MA
Michael C. Appel - Grafton MA
Nancy E. Phillips - Shrewsbury MA
John P. Mordes - Newton MA
Dale L. Grenier - Hubbardston MA
Aldo A. Rossini - Sudbury MA

Assignee:

University of Massachusetts Medical Center - Worcester MA
The Trustees of Dartmouth College - Hanover NH

International Classification:

A61K39/395;35/26

US Classification:

4241441

Abstract:

Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.

US Patent:

56836937, Nov 4, 1997

Filed:

Apr 25, 1994

Appl. No.:

8/234987

Inventors:

Randolph J. Noelle - Cornish NH
Fiona H. Durie - Seattle WA
David C. Parker - Grafton MA
Michael C. Appel - Grafton MA
Nancy E. Phillips - Shrewsbury MA
John P. Mordes - Newton MA
Dale L. Grenier - Hubbardston MA
Aldo A. Rossini - Sudbury MA

Assignee:

Trustees of Dartmouth College - Hanover NH
University of Massachusetts Medical Center - Worcester MA

International Classification:

A61K 39395
A61K 3817

US Classification:

4241441

Abstract:

Methods for inducing T cell unresponsiveness to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.